Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Standard
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. / Shariat, Shahrokh F; Walz, Jochen; Roehrborn, Claus G; Montorsi, Francesco; Jeldres, Claudio; Saad, Fred; Karakiewicz, Pierre I.
in: J UROLOGY, Jahrgang 179, Nr. 4, 4, 2008, S. 1593-1597.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
AU - Shariat, Shahrokh F
AU - Walz, Jochen
AU - Roehrborn, Claus G
AU - Montorsi, Francesco
AU - Jeldres, Claudio
AU - Saad, Fred
AU - Karakiewicz, Pierre I
PY - 2008
Y1 - 2008
N2 - PURPOSE: Blood levels of transforming growth factor-beta1, interleukin-6 and interleukin-6 soluble receptor have been associated with aggressive primary and metastatic prostate cancer. We hypothesized that patients with increased plasma levels of transforming growth factor-beta1, interleukin-6 and/or interleukin-6 soluble receptor after radical prostatectomy would be more likely to harbor occult metastases, leading to disease progression despite effective local control of disease. MATERIALS AND METHODS: Plasma transforming growth factor-beta1, interleukin-6 and interleukin-6 soluble receptor were measured 6 to 8 weeks after surgery in 291 consecutive patients treated with radical prostatectomy for clinically localized disease. Discrimination and validation of multivariate Cox regression models targeting time to biochemical progression were used to quantify the added value of these markers to predictive accuracy (concordance index) after internal validation with 200 bootstrap resamples. RESULTS: On multivariate analysis adjusting for standard postoperative features postoperative plasma transforming growth factor-beta1 was the only biomarker independently associated with biochemical progression (p
AB - PURPOSE: Blood levels of transforming growth factor-beta1, interleukin-6 and interleukin-6 soluble receptor have been associated with aggressive primary and metastatic prostate cancer. We hypothesized that patients with increased plasma levels of transforming growth factor-beta1, interleukin-6 and/or interleukin-6 soluble receptor after radical prostatectomy would be more likely to harbor occult metastases, leading to disease progression despite effective local control of disease. MATERIALS AND METHODS: Plasma transforming growth factor-beta1, interleukin-6 and interleukin-6 soluble receptor were measured 6 to 8 weeks after surgery in 291 consecutive patients treated with radical prostatectomy for clinically localized disease. Discrimination and validation of multivariate Cox regression models targeting time to biochemical progression were used to quantify the added value of these markers to predictive accuracy (concordance index) after internal validation with 200 bootstrap resamples. RESULTS: On multivariate analysis adjusting for standard postoperative features postoperative plasma transforming growth factor-beta1 was the only biomarker independently associated with biochemical progression (p
M3 - SCORING: Zeitschriftenaufsatz
VL - 179
SP - 1593
EP - 1597
JO - J UROLOGY
JF - J UROLOGY
SN - 0022-5347
IS - 4
M1 - 4
ER -
